# A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

> **NCT00381173** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 22 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Colon Cancer
- Renal Cancer

## Interventions

- **DRUG:** Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)

## Key facts

- **NCT ID:** NCT00381173
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381173, "A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00381173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*